{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:43:23Z","timestamp":1784249003447,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,18]]},"DOI":"10.7759\/cureus.101806","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:08:48Z","timestamp":1768788528000},"source":"Crossref","is-referenced-by-count":1,"title":["Progesterone Enhances the Sensitivity of Ovarian Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibitors by Suggesting a Role for Transcription-Replication Conflict-Related Pathways: An In Vitro Study"],"prefix":"10.7759","author":[{"given":"Eri","family":"Suizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Saga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyo","family":"Taneichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mizukami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025, 75:10-45. 10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"ref2","unstructured":"Cancer stat facts. ovarian cancer. (2025). Accessed: January 17, 2026: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra SA","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004, 351:2519-29. 10.1056\/NEJMra041842","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2012.9002","article-title":"Recent advances in systemic treatments for ovarian cancer","volume":"12","author":"Banerjee S","year":"2012","unstructured":"Banerjee S, Gore M. Recent advances in systemic treatments for ovarian cancer. Cancer Imaging. 2012, 12:305-9. 10.1102\/1470-7330.2012.9002","journal-title":"Cancer Imaging"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1304303","article-title":"Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice","volume":"13","author":"Romero I","year":"2024","unstructured":"Romero I, Guerra E, Madariaga A, Manso L. Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice. Front Oncol. 2024, 13:1304303. 10.3389\/fonc.2023.1304303","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore K","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, et al.. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018, 379:2495-505. 10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn A","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, et al.. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019, 381:2391-402. 10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday T","year":"2011","unstructured":"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011, 5:387-93. 10.1016\/j.molonc.2011.07.001","journal-title":"Mol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos M","year":"2024","unstructured":"Petropoulos M, Karamichali A, Rossetti GG, et al.. Transcription-replication conflicts underlie sensitivity to PARP inhibitors. Nature. 2024, 628:433-41. 10.1038\/s41586-024-07217-2","journal-title":"Nature"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-023-04738-3","article-title":"The TIMELESS effort for timely DNA replication and protection","volume":"80","author":"Patel JA","year":"2023","unstructured":"Patel JA, Kim H. The TIMELESS effort for timely DNA replication and protection. Cell Mol Life Sci. 2023, 80:84. 10.1007\/s00018-023-04738-3","journal-title":"Cell Mol Life Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/rep.1.00189","article-title":"Reproductive tissue selective actions of progesterone receptors","volume":"128","author":"Mulac-Jericevic B","year":"2004","unstructured":"Mulac-Jericevic B, Conneely OM. Reproductive tissue selective actions of progesterone receptors. Reproduction. 2004, 128:139-46. 10.1530\/rep.1.00189","journal-title":"Reproduction"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061799","article-title":"Do not forget about hormonal therapy for recurrent endometrial cancer: a review of options, updates, and new combinations","volume":"15","author":"Wagner VM","year":"2023","unstructured":"Wagner VM, Backes FJ. Do not forget about hormonal therapy for recurrent endometrial cancer: a review of options, updates, and new combinations. Cancers (Basel). 2023, 15:1799. 10.3390\/cancers15061799","journal-title":"Cancers (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac184","article-title":"Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive\/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study","volume":"53","author":"Kawaguchi H","year":"2023","unstructured":"Kawaguchi H, Yamamoto Y, Saji S, et al.. Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive\/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study. Jpn J Clin Oncol. 2023, 53:203-11. 10.1093\/jjco\/hyac184","journal-title":"Jpn J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0336132100","article-title":"Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes","volume":"100","author":"Zhu Y","year":"2003","unstructured":"Zhu Y, Rice CD, Pang Y, Pace M, Thomas P. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci U S A. 2003, 100:2231-6. 10.1073\/pnas.0336132100","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111785","article-title":"Membrane progesterone receptors (mPRs, PAQRs): review of structural and signaling characteristics","volume":"11","author":"Thomas P","year":"2022","unstructured":"Thomas P. Membrane progesterone receptors (mPRs, PAQRs): review of structural and signaling characteristics. Cells. 2022, 11:1785. 10.3390\/cells11111785","journal-title":"Cells"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1934","article-title":"The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death","volume":"7","author":"Koyanagi T","year":"2024","unstructured":"Koyanagi T, Saga Y, Takahashi Y, et al.. The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death. Cancer Rep (Hoboken). 2024, 7:e1934. 10.1002\/cnr2.1934","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70202","article-title":"Progesterone enhances sensitivity of ovarian cancer cells to SN38 through inhibition of topoisomerase I and inducing ferroptosis","volume":"8","author":"Koyanagi T","year":"2025","unstructured":"Koyanagi T, Saga Y, Takahashi Y, et al.. Progesterone enhances sensitivity of ovarian cancer cells to SN38 through inhibition of topoisomerase I and inducing ferroptosis. Cancer Rep (Hoboken). 2025, 8:e70202. 10.1002\/cnr2.70202","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1159\/000226813","article-title":"Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen","volume":"47","author":"Imai S","year":"1990","unstructured":"Imai S, Kiyozuka Y, Maeda H, Noda T, Hosick HL. Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. Oncology. 1990, 47:177-84. 10.1159\/000226813","journal-title":"Oncology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11364","article-title":"Pharmacological ascorbate induces \u2018BRCAness\u2019 and enhances the effects of poly(ADP-ribose) polymerase inhibitors against BRCA1\/2 wild-type ovarian cancer","volume":"19","author":"Ma Y","year":"2020","unstructured":"Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q. Pharmacological ascorbate induces \u2018BRCAness\u2019 and enhances the effects of poly(ADP-ribose) polymerase inhibitors against BRCA1\/2 wild-type ovarian cancer. Oncol Lett. 2020, 19:2629-38. 10.3892\/ol.2020.11364","journal-title":"Oncol Lett"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.41.23922","article-title":"The transcriptional elongation inhibitor 5,6-dichloro-1-\u03b2-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase","volume":"270","author":"Yankulov K","year":"1995","unstructured":"Yankulov K, Yamashita K, Roy R, Egly JM, Bentley DL. The transcriptional elongation inhibitor 5,6-dichloro-1-\u03b2-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase. J Biol Chem. 1995, 270:23922-5. 10.1074\/jbc.270.41.23922","journal-title":"J Biol Chem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2020.1843951","article-title":"Topoisomerase I prevents transcription-replication conflicts at transcription termination sites","volume":"8","author":"Liu Y","year":"2020","unstructured":"Liu Y, Lin YL, Pasero P, Chen CL. Topoisomerase I prevents transcription-replication conflicts at transcription termination sites. Mol Cell Oncol. 2020, 8:1843951. 10.1080\/23723556.2020.1843951","journal-title":"Mol Cell Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee S","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, et al.. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021, 22:1721-31. 10.1016\/S1470-2045(21)00531-3","journal-title":"Lancet Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso D","year":"2024","unstructured":"Lorusso D, Mouret-Reynier MA, Harter P, et al.. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial. Int J Gynecol Cancer. 2024, 34:550-8. 10.1136\/ijgc-2023-004995","journal-title":"Int J Gynecol Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-012-0041-9","article-title":"Bevacizumab in the treatment of ovarian cancer","volume":"29","author":"Heitz F","year":"2012","unstructured":"Heitz F, Harter P, Barinoff J, et al.. Bevacizumab in the treatment of ovarian cancer. Adv Ther. 2012, 29:723-35. 10.1007\/s12325-012-0041-9","journal-title":"Adv Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00217-8","article-title":"Evaluating progestogens for preventing preterm birth international collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials","volume":"397","author":"Stewart LA","year":"2021","unstructured":"Stewart LA, Simmonds M, Duley L, et al.. Evaluating progestogens for preventing preterm birth international collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet. 2021, 397:1183-94. 10.1016\/S0140-6736(21)00217-8","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1909786","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"383","author":"Merke DP","year":"2020","unstructured":"Merke DP, Auchus RJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 2020, 383:1248-61. 10.1056\/NEJMra1909786","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/438132-progesterone-enhances-the-sensitivity-of-ovarian-cancer-cells-to-poly-adp-ribose-polymerase-parp-inhibitors-by-suggesting-a-role-for-transcription-replication-conflict-related-pathways-an-in-vitro-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T02:08:49Z","timestamp":1768788529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/438132-progesterone-enhances-the-sensitivity-of-ovarian-cancer-cells-to-poly-adp-ribose-polymerase-parp-inhibitors-by-suggesting-a-role-for-transcription-replication-conflict-related-pathways-an-in-vitro-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.101806","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,18]]}}}